2014

The Ovarian Cancer Drug Market is Set to More Than Double to $1.6 Billion by 2022 Penetration of Avastin in Multiple Market Segments and Approval of Seven Novel Premium-Priced Therapies Will Drive Market Growth, According to Findings from Decision Resources

BURLINGTON, Mass., Dec. 11, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Roche/Genentech/Chugai's Avastin will penetrate nearly all segments of the ovarian cancer market through 2022, driving growth of the angiogenesis inhibitor drug class and contributing to annual growth of approximately 10 percent in the overall ovarian cancer market. In addition, the launch of three new angiogenesis inhibitors, Amgen's trebananib, Boehringer Ingelheim's nintedanib and GlaxoSmithKline's Votrient, will contribute to sales within this drug class, which is set to continue to dominate the treatment of ovarian cancer, accounting for 58 percent of total sales in 2022.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor Ovarian Cancer advisory service also anticipates market entrants from three novel drug classes to ovarian cancer—Merck's folate receptor-targeting small-molecule drug conjugate vintafolide, the poly (ADP-ribose) polymerase inhibitors olaparib (AstraZeneca) and niraparib (Tesaro) and Array BioPharma/Novartis's MEK inhibitor MEK162. Experts interviewed for the report indicate that with the anticipated availability of numerous targeted agents in the treatment of ovarian cancer, determining the optimal sequencing of chemotherapy and targeted treatment options for patients progressing through numerous lines of therapy will become increasingly important.

"The ovarian cancer market is set to become crowded with targeted agents—in particular, with therapies targeting angiogenesis," said Decision Resources Senior Analyst Gemma McConnell, Ph.D. "Emerging therapies in this drug class will face strong competition from the currently available therapy, Avastin, as well as from each other, therefore it will become increasingly important for agents to distinguish themselves from each other. When selecting a treatment option, oncologists will consider the specific patient population in which each agent has demonstrated the greatest efficacy, the agent's dosing schedule and associated toxicity profile, among other factors."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources



RELATED LINKS
http://www.decisionresources.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.